肿瘤细胞治疗研究
英文原题：The paths toward immunotherapy of esophageal cancer: An overview of clinical trials.
作为全球癌症相关死亡第七大贡献者，食管癌（EC）是最具挑战性的癌症类型之一。
作为全球癌症相关死亡的第七大贡献者，食管癌（EC）是最具挑战性的癌症类型之一。尽管包括手术、化疗和放疗在内的传统疗法取得了进展，但五年生存率仍然很低，这凸显了开发更有效治疗方法的必要性。免疫疗法已成为一种有前景的治疗方法，为EC患者带来了新的希望。本综述深入探讨了EC的最新免疫治疗策略，重点关注免疫检查点抑制剂、过继细胞疗法、癌症疫苗和溶瘤病毒疗法。我们批判性地分析了当前的临床数据，以突出每种免疫治疗方法在EC中的进展和缺陷。此外，我们探索了联合疗法的潜力，这可能克服单一疗法中常见的耐药性。最后，我们讨论了当前治疗的局限性，并概述了未来研究的关键领域，以改善患者预后和生存。
As the seventh-leading contributor to global cancer-related deaths, esophageal cancer (EC) is one of the most challenging types of cancer. Despite advancements in conventional therapies, including surgery, chemotherapy, and radiotherapy, the five-year survival rate remains low, underscoring the need for the development of more efficacious treatment approaches. Immunotherapy has emerged as a promising treatment approach, offering new hope for EC patients. This review provides an in-depth examination of the latest immunotherapeutic strategies for EC, focusing on immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and oncolytic virotherapy. We critically analyze the current clinical data to highlight the progress and pitfalls of each immunotherapeutic approach for EC. Additionally, we explore the potential for combination therapies, which could overcome the resistance often seen with monotherapies. Finally, we discuss the limitations of current treatments and outline key areas for future research to improve patient outcomes and survival.
MEMBER ACCOUNT
登录成功会直接打开下一页。
